-
公开(公告)号:EP2509950A1
公开(公告)日:2012-10-17
申请号:EP10790938.4
申请日:2010-12-10
申请人: Janssen R&D Ireland , Medivir AB
发明人: KALAYANOV, Genadiy , KESTELEYN, Bart, Rudolf, Romanie , PARKES, Kevin , SAMUELSSON, Bengt, Bertil , SCHEPENS, Wim, Bert, Griet , THURING, Johannes, Wilhelmus, J. , WALLBERG, Hans, Kristian , WEGNER, Jörg, Kurt
IPC分类号: C07D213/64 , C07D213/74 , C07D277/30 , C07D401/12 , C07D405/12 , C07D417/12 , C07D493/04 , A61K31/506 , A61P31/18
CPC分类号: C07D213/64 , C07D213/74 , C07D277/30 , C07D401/12 , C07D405/12 , C07D417/12 , C07D493/04
摘要: HIV inhibitors of formula (I) wherein R
1 is halo, C
1-4 alkoxy, trifluoromethoxy; R
2 is a group of formula (A); R
3 is a group of formula (B); R
4 is a group of formula (C); n is 0 or 1; A is CH or N; R
5 and R
6 are hydrogen, C
1-4 alkyl, halo; R
7 and R
8 are C
1-4 alkyl or C
1-4 alkoxyC
1-4 alkyl; R
9 is C
1-4 alkyl, cyclopropyl, trifluoromethyl, C
1-4 alkoxy, or dimethylamino; R
10 is hydrogen, C
1-4 alkyl, cyclopropyl, trifluoromethyl, C
1-4 alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.摘要翻译: 式(I)的HIV抑制剂,其中R 1是卤素,C 1-4烷氧基,三氟甲氧基; R 2是式(A)的基团; R 3是式(B)的基团; R 4是式(C)的基团; n是0或1; A是CH或N; R 5和R 6是氢,C 1-4烷基,卤素; R 7和R 8是C 1-4烷基或C 1-4烷氧基C 1-4烷基; R 9是C 1-4烷基,环丙基,三氟甲基,C 1-4烷氧基或二甲氨基; R 10为氢,C 1-4烷基,环丙基,三氟甲基,C 1-4烷氧基或二甲基氨基; 药学上可接受的加成盐和溶剂合物; 含有这些化合物作为活性成分的药物组合物和制备所述化合物的方法。
-
公开(公告)号:EP2509950B1
公开(公告)日:2015-02-25
申请号:EP10790938.4
申请日:2010-12-10
申请人: Janssen R&D Ireland , Medivir AB
发明人: KALAYANOV, Genadiy , KESTELEYN, Bart, Rudolf, Romanie , PARKES, Kevin , SAMUELSSON, Bengt, Bertil , SCHEPENS, Wim, Bert, Griet , THURING, Johannes, Wilhelmus, J. , WALLBERG, Hans, Kristian , WEGNER, Jörg, Kurt
IPC分类号: C07D213/64 , C07D213/74 , C07D277/30 , C07D401/12 , C07D405/12 , C07D417/12 , C07D493/04 , A61K31/506 , A61P31/18
CPC分类号: C07D213/64 , C07D213/74 , C07D277/30 , C07D401/12 , C07D405/12 , C07D417/12 , C07D493/04
-
公开(公告)号:EP2111396B1
公开(公告)日:2013-08-07
申请号:EP08708828.2
申请日:2008-02-08
申请人: Janssen R&D Ireland , Medivir AB
发明人: RABOISSON, Pierre Jean-Marie Bernard , ANTONOV, Dmitry , AYESA ALVAREZ, Susana , BELFRAGE, Anna, Karin, Gertrud, Linnea , JÖNSSON, Carl, Erik, Daniel , MC GOWAN, David, Craig , NILSSON, Karl, Magnus , ROSENQUIST, Åsa, Annica, Kristina , SAMUELSSON, Bengt, Bertil
IPC分类号: C07D245/04 , C07D255/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D498/04 , C07D498/14 , A61K31/538 , A61P31/14
CPC分类号: C07D245/04 , C07D255/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D498/04 , C07D498/14
-
公开(公告)号:EP2118091A1
公开(公告)日:2009-11-18
申请号:EP08708826.6
申请日:2008-02-08
发明人: RABOISSON, Pierre Jean-Marie Bernard , BELFRAGE, Anna, Karin, Gertrud, Linnea , CLASSON, Björn, Olof , LINDQUIST, Karin, Charlotta , NILSSON, Karl, Magnus , ROSENQUIST, Åsa, Annica, Kristina , SAMUELSSON, Bengt, Bertil , WÄHLING, Horst, Jürgen
IPC分类号: C07D403/12 , C07K5/06
CPC分类号: C07K5/06165 , A61K38/00 , C07D403/12 , Y02A50/385 , Y02A50/387
摘要: Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
-
公开(公告)号:EP1005493B1
公开(公告)日:2005-11-02
申请号:EP98915095.8
申请日:1998-04-03
申请人: MEDIVIR AB
CPC分类号: C07D213/30 , C07C235/14 , C07C237/22 , C07C2601/02 , C07C2601/16 , C07C2602/08 , C07D213/40 , C07D277/24 , C07D309/10 , C07D333/16 , C07D405/12 , C07D407/12 , C07D493/04
摘要: Compounds of formula (I), wherein A' and A'' are independently the same or different group of formula (II) wherein: R' is H, CH3, C(CH3)2, -OR?a, -N(Ra)¿2, -N(Ra)ORa or -DP; R''' is H or CH¿3; R?a is H, C¿1?-C3 alkyl; D is a bond, alkylene, -C(=O)-, -S(O)- or -S(O)2-; P is an optionally substituted, mono or bicyclic carbo- or heterocycle; R'' is H, any of the sidechains found in the natural amino acids, carboxacetamide, or a group (CH2)nDP; M is a bond or -C(=O)N(R''')-; Q is absent, a bond, -CH(OH)- or -CH2-; or R'' together with Q, M and R' define an optionally substituted 5 or 6 membered carbo- or heterocyclic ring which is optionally fused with a further 5 or 6 membered carbo- or heterocyclic ring; with the proviso that R' is -OR?a, -N(Ra)¿2, -N(Ra)ORa or -DP, if M is a bond and Q is absent; X is H, OH, OCH¿3?; Y is H, OH, OCH3, but X and Y are not both H; Z' and Z'' are independently -(CH2)mP where P is as defined above; n and m are independently 0, 1 or 2; and pharmaceutically acceptable salts and prodrugs thereof have utility as aspartyl protease inhibitors of HIV. They can be prepared in a facile two step synthesis from novel 2,5-di-O-benzyl-L-mannaro-1,4:6,3-dilactone intermediates.
-
公开(公告)号:EP2118091B1
公开(公告)日:2015-04-15
申请号:EP08708826.6
申请日:2008-02-08
发明人: RABOISSON, Pierre Jean-Marie Bernard , BELFRAGE, Anna, Karin, Gertrud, Linnea , CLASSON, Björn, Olof , LINDQUIST, Karin, Charlotta , NILSSON, Karl, Magnus , ROSENQUIST, Åsa, Annica, Kristina , SAMUELSSON, Bengt, Bertil , WÄHLING, Horst, Jürgen
IPC分类号: C07D403/12 , C07K5/06
CPC分类号: C07K5/06165 , A61K38/00 , C07D403/12 , Y02A50/385 , Y02A50/387
摘要: Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
-
公开(公告)号:EP2111396A1
公开(公告)日:2009-10-28
申请号:EP08708828.2
申请日:2008-02-08
发明人: RABOISSON, Pierre Jean-Marie Bernard , ANTONOV, Dmitry , AYESA ALVAREZ, Susana , BELFRAGE, Anna, Karin, Gertrud, Linnea , JÖNSSON, Carl, Erik, Daniel , MC GOWAN, David, Craig , NILSSON, Karl, Magnus , ROSENQUIST, Åsa, Annica, Kristina , SAMUELSSON, Bengt, Bertil
IPC分类号: C07D245/04 , C07D255/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D498/04 , C07D498/14 , A61K31/538 , A61P31/14
CPC分类号: C07D245/04 , C07D255/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D498/04 , C07D498/14
摘要: Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof;usefulas HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
摘要翻译: 包含其立体异构体或N-氧化物,药学上可接受的加成盐或其药学上可接受的加成溶剂化物的式(I)化合物;有用的HCV抑制剂; 制备这些化合物的方法以及包含这些化合物作为活性成分的药物组合物。
-
公开(公告)号:EP1005493A1
公开(公告)日:2000-06-07
申请号:EP98915095.8
申请日:1998-04-03
申请人: MEDIVIR AB
CPC分类号: C07D213/30 , C07C235/14 , C07C237/22 , C07C2601/02 , C07C2601/16 , C07C2602/08 , C07D213/40 , C07D277/24 , C07D309/10 , C07D333/16 , C07D405/12 , C07D407/12 , C07D493/04
摘要: Compounds of formula (I), wherein A' and A'' are independently the same or different group of formula (II) wherein: R' is H, CH3, C(CH3)2, -OR?a, -N(Ra)¿2, -N(Ra)ORa or -DP; R''' is H or CH¿3; R?a is H, C¿1?-C3 alkyl; D is a bond, alkylene, -C(=O)-, -S(O)- or -S(O)2-; P is an optionally substituted, mono or bicyclic carbo- or heterocycle; R'' is H, any of the sidechains found in the natural amino acids, carboxacetamide, or a group (CH2)nDP; M is a bond or -C(=O)N(R''')-; Q is absent, a bond, -CH(OH)- or -CH2-; or R'' together with Q, M and R' define an optionally substituted 5 or 6 membered carbo- or heterocyclic ring which is optionally fused with a further 5 or 6 membered carbo- or heterocyclic ring; with the proviso that R' is -OR?a, -N(Ra)¿2, -N(Ra)ORa or -DP, if M is a bond and Q is absent; X is H, OH, OCH¿3?; Y is H, OH, OCH3, but X and Y are not both H; Z' and Z'' are independently -(CH2)mP where P is as defined above; n and m are independently 0, 1 or 2; and pharmaceutically acceptable salts and prodrugs thereof have utility as aspartyl protease inhibitors of HIV. They can be prepared in a facile two step synthesis from novel 2,5-di-O-benzyl-L-mannaro-1,4:6,3-dilactone intermediates.
摘要翻译: 式I的化合物:其中:A'和A“独立地是相同或不同的式II的基团:其中:R'是H,CH 3,C(CH 3)2,-OR a,-N(R a)2,-N(R a)OR a或-DP R“'是H或CH 3; R a是H,C 1 -C 3烷基; D是键,亚烷基,-C(= O) - , - (O) - 或-S(O)2 - ; P是任选取代的单或双环碳 - 或杂环; R“是H,在天然氨基酸中发现的任何侧链,羧基乙酰胺或 一组(CH 2)n DP; M是键或-C(= O)N(R“') - ; Q不存在,键,-CH(OH) - 或-CH 2 - ; 或R“连同Q,M和R'定义任选取代的5或6元碳环或杂环,其任选地与另外的5或6元碳 - 或杂环稠合;条件是R'为-OR a,-N(R a)2,-N(R a)OR a或-DP,如果M是键且Q不存在; X是H,OH,OCH 3; Y是H,OH,OCH 3, 但X和Y不同时为H; Z'和Z“独立地为 - (CH 2)m P,其中P如上定义; n和m独立地为0,1或2; 其药学上可接受的盐和前药具有作为HIV的天冬氨酰蛋白酶抑制剂的效用。 它们可以通过新的2,5-di-O-苄基-L-肉豆蔻-4,4:6,3-二酮中间体的容易的两步合成来制备。
-
-
-
-
-
-
-